Advanced search
Publication Cover
Acta Cardiologica Volume 70, 2015 - Issue 5
Submit an article Journal homepage
23
Views
2
CrossRef citations to date
0
Altmetric
Original Articles

Active and total myeloperoxidase in coronary artery disease and relation to clinical instability

Olivier GachUniversity of Liège, Centre Hospitalier Universitaire du Sart Tilman, Service de Cardiologie, Domaine Universitaire du Sart Tilman (B 35), Liège, BelgiumCorrespondence[email protected]
, Md, Phd,
Cédric BrogneauxUniversity of Liège, Centre Hospitalier Universitaire du Sart Tilman, Service de Cardiologie, Domaine Universitaire du Sart Tilman (B 35), Liège, Belgium
, Md,
ThIerry FranckUniversity of Liège. Anesthesiology et Surgical Pathology, Institut Vétérinaire, Domaine Universitaire du Sart Tilman (B 41), Liège, Belgium;University of Liège, Centre for Oxygen, Research and Development (CORD), Institute of Chemistry (B6a), Domaine du Sart Tilman, Liège, Belgium.
, DVM,
Didier SerteynUniversity of Liège. Anesthesiology et Surgical Pathology, Institut Vétérinaire, Domaine Universitaire du Sart Tilman (B 41), Liège, Belgium;University of Liège, Centre for Oxygen, Research and Development (CORD), Institute of Chemistry (B6a), Domaine du Sart Tilman, Liège, Belgium.
, DVM, Phd,
Victor LegrandUniversity of Liège, Centre Hospitalier Universitaire du Sart Tilman, Service de Cardiologie, Domaine Universitaire du Sart Tilman (B 35), Liège, Belgium
, Md, Phd,
Luc A. PierardUniversity of Liège, Centre Hospitalier Universitaire du Sart Tilman, Service de Cardiologie, Domaine Universitaire du Sart Tilman (B 35), Liège, Belgium
, Md, Phd &
Julien MagneUniversity of Liège, Centre Hospitalier Universitaire du Sart Tilman, Service de Cardiologie, Domaine Universitaire du Sart Tilman (B 35), Liège, Belgium
, Phd show all
Pages 522-527 | Received 26 Feb 2015, Accepted 24 Mar 2015, Published online: 23 May 2017

References

  • Zhang R, Brennan ML, Fu X, Aviles RI, Pearce GL, Penn MS, Topol EJ, Sprecher DL, Hazen SL. Association between myeloperoxidase levels and risk of coronary artery disease. JAMA 2001; 286: 2136–42.
  • Baldus S. Heeschen C, Meinertz T, Zeiher AM, Eiserich JP, Miinzel T, Simoons ML, Hamm CW. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation 2003; 108: 1440–5.
  • Gach O, Biérnar C, Nys M, Deby-Dupont G, Chapelle JP, Deby C, Lamy M, Piérard LA, Legrand V. Early release of neutrophil markers of activation after direct stenting in patients with unstable angina. Coron Artery Dis 2005; 16: 59–65.
  • Gach O, Nys M, Deby-Dupont G, Chapelle JP, Lamy M, Piérard LA, Legrand V. Acute neutrophil activation in direct stenting: comparison of stable and unstable angina patients. Int J Cardiol 2006; 112: 59–65.
  • Brennan ML, Penn MS, Van Lente F, Nambi V, Shishehbor MH, Aviles RJ, Goormastic M, Pepoy ML, McErlean ES, Topol EJ, Nissen SE, Hazen SL. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med 2003; 349:1595–604.
  • Pincemail J, Deby-Dupont G, Deby C, Thirion A, Torpier G, Faymonville ME, Da mas P. Tomassini M, Lamy M, Franchimont P. Fast double antibody radioimmunoassay of human granulocyte myeloperoxidase and its application to plasma. J Immunol Methods 1991; 137:181–91.
  • Malle E, Furtmiiller PG, Sattler W, Obinger C. Myeloperoxidase: a target for new drug development? Br J Pharmacol 2007; 152:838–54.
  • De la Harpe J, Nathan CF. A semi-automated micro-assay for H202 release by human blood monocytes and mouse peritoneal macrophages. JImmuno/Methods 1985; 78:323–36.
  • FranckT, Kohnen 5, Deby-Dupont G, Grulke 5, Deby C, Serteyn D. A specific method for measurement of equine active myeloperoxidase in biological samples and in in vitro tests. J Vet Diagn Invest 2006; 18: 326–34.
  • FranckT, Kohnen 5, Boudjeltia KZ, Van Antwerpen P. Bosseloir A, Niesten A, Gach O, Nys M, Deby-Dupont G, Serteyn D. A new easy method for specific measurement of active myeloperoxidase in human biological fluids and tissue extracts. Ta/anta 2009; 80: 723–9.
  • Davies MJ, Hawkins CL, Pattison Di, Rees MD. Mammalian heme peroxidases: from molecular mechanisms to health implications. Anti oxid Redox Signal 2008; 10: 1199–234.
  • Lau D, Mollnau H, Eiserich JP, Freeman BA, Daiber A, Gehling UM, Briimmer J, Rudolph V, Munzel T, Heitzer T, Meinertz T, Baldus S. Myeloperoxidase mediates neutrophil activation by association with CD11b/CD18 integrins. Proc Natl Acad Sci USA 2005; 102: 431–6.
  • Zhang R, Brennan ML, Shen Z, MacPherson JC, Schmitt D, Molenda CE, Hazen SL. Myeloperoxidase functions as a major enzymatic catalyst for initiation of lipid peroxidation at sites of inflammation. J Biol Chem 2002; 277: 46116–22.
  • Gach O, MagneJ, Franck T, Derochette 5, Deby G, Serteyn D, Defraigne JO, Lancellotti P. Legrand V. Pierard LA. Clinical significance of active myeloperoxidase in carotid atherosclerotic plaques. Int J Cardiol 2011; 152:149–51.
  • Meuwese MC, Stroes ES, Hazen SL, van Miert JN, Kuivenhoven JA, Schaub RG, Wareham NJ, Luben R, Kastelein JJ, Khaw KT, Boekholdt SM. Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals: the EPIC-Norfolk Prospective Population Study. J Am Coll Cardiol 2007; 50: 159–65.
  • Cavusoglu E, Ruwende C, Eng C, Chopra V. Yanamadala 5, Clark LT, Pinsky DJ, Marmur JD. Usefulness of baseline plasma myeloperoxidase levels as an independent predictor of myocardial infarction at two years in patients presenting with acute coronary syndrome. Am J Cardiol 2007; 99: 1364–8.
  • Mocatta TJ, Pilbrow AP, Cameron VA, Senthilmohan R, Frampton CM, Richards AM, Winterbourn CC. Plasma concentrations of myeloperoxidase predict mortality after myocardial infarction. J Am Coll Cardiol 2007; 49: 1993–2000.
  • Baldus S, Heeschen C, Meinertz T, Zeiher AM, Eiserich JP, Miinzel T, Simoons ML, Hamm CW; CAPTURE Investigators. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation 2003; 108: 1440–5.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Novo Nordisk – Driving change to defeat serious chronic diseases.
A bold vision to stop cardiovascular disease from being a leading cause of death.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.